Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer
Journal for ImmunoTherapy of Cancer · 2026-03 · 14 (3) · e014365
DOI: 10.1136/jitc-2025-014365 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 25.03.2026. Verfasst von Chennan Li und 27 weiteren Autor:innen. Beteiligte Einrichtung: Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Piperazines, Antibodies, Monoclonal, Phthalazines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Department of Defense Prostate Cancer Research Program, National Cancer Institute, Astra Zeneca.
Abstract (Originalsprache)
Background
Poly(ADP-ribose) polymerase (PARP) inhibition (PARPi) is a precision medicine strategy in advanced prostate cancer, with the greatest benefit seen in a subset of patients with homologous recombination repair (HRR) gene alterations. Combination approaches may expand activity beyond HRR-altered disease. We conducted a phase 2 study of the PARP inhibitor olaparib in combination with the anti-PD-L1 antibody durvalumab in an HRR-unselected population of men with metastatic castration-resistant prostate cancer (mCRPC).
Methods
This is a single-arm, open-label phase 2 trial of olaparib plus durvalumab in men with mCRPC previously treated with abiraterone and/or enzalutamide. Pretreatment biopsies of metastatic lesions were attempted for tumor sequencing. Peripheral blood was collected longitudinally for immune profiling of cell subsets and soluble factors, circulating tumor DNA (ctDNA) analyses, and peripheral blood mononuclear cell (PBMC) gene expression profiling.
Results
61 patients were enrolled; 60 were evaluable. Median age was 65 years (45–88). Median radiographic progression-free survival (rPFS) was 5.0 months (95% CI 4.6 to 7.6) and median overall survival (OS) was 19.1 months (95% CI 15.0 to 29.3 months). 10 patients achieved partial responses, and 17 (28%) had ≥50% prostate-specific antigen declines. Patients with BRCA2 variants experienced longer rPFS (13.2 months; 95% CI 7.7 to 20.2 months) than patients without BRCA2 variants (4.8 months; 95% CI 4.5 to 6.4 months, p=0.0026). Baseline ctDNA fraction was higher in patients with radiographic progression than in those with partial response (p=0.022) and inversely correlated with time-to-progression (ρ=−0.51). Treatment- induced early peripheral immune perturbations included transient inflammatory cytokine increases and expansion of activated/proliferating T cells with concurrent regulatory features. Exploratory PBMC profiling identified IL1R2 as a response-associated transcript, and lower IL1R2 expression was associated with longer OS.
Conclusions
Olaparib plus durvalumab demonstrated modest activity in HRR-unselected mCRPC, with clinical benefit enriched in BRCA2 -variant disease. Integrated ctDNA and peripheral immune analyses support ongoing efforts to refine molecular and immune selection strategies and to better define mechanisms of benefit and resistance for combination approaches in mCRPC. Trial registration number NCT02484404 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.
- Developmental Therapeutics Branch, National Cancer Institute, Bethesda, Maryland, USA.
- Inova Schar Cancer Institute, Fairfax, Virginia, USA.
- Center for Immuno-Oncology, National Cancer Institute, Bethesda, Maryland, USA.
- Genetics Branch, National Cancer Institute, Bethesda, Maryland, USA.
- Women's Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.
Förderung
- Department of Defense Prostate Cancer Research Program
- National Cancer Institute
- Astra Zeneca
Zitieren
APA
Li, C., Madan, R. A., Lee, M. J., Lee, S., Sato, N., Rastogi, S., Shrestha, R., Aragon-Ching, J. B., Goswami, M., Donahue, R. N., Cordes, L. M., Baj, A., Seo, C. C. Y., Terrigino, N. T., Bright, J. R., Hennigan, S. T., King, I. M., Trostel, S. Y., Fenimore, J. M., …, & Karzai, F. (2026). Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer. Journal for ImmunoTherapy of Cancer, 14(3), e014365. https://doi.org/10.1136/jitc-2025-014365
Vancouver
Li C, Madan RA, Lee MJ, Lee S, Sato N, Rastogi S, et al. Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer. Journal for ImmunoTherapy of Cancer. 2026;14(3):e014365. doi:10.1136/jitc-2025-014365
BibTeX
@article{Li2026,
author = {Li, Chennan and Madan, Ravi A and Lee, Min-Jung and Lee, Sunmin and Sato, Nahoko and Rastogi, Shraddha and Shrestha, Roshan and Aragon-Ching, Jeanny B and Goswami, Meghali and Donahue, Renee N and Cordes, Lisa M and Baj, Anna and Seo, Clara C Y and Terrigino, Nicholas T and Bright, John R and Hennigan, S Thomas and King, Isaiah M and Trostel, Shana Y and Fenimore, John M and Liu, Yi and Calzone, Kathleen A and Schlom, Jeffrey and Gulley, James L and Dahut, William L and Figg, William D and Sowalsky, Adam G and Lee, Jung-Min and Karzai, Fatima},
title = {Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {3},
pages = {e014365},
doi = {10.1136/jitc-2025-014365}
}
EUVIMED